We offer a complete product line of radiopharmaceuticals. We are a problem-solving pharmacy that works with physicians, technologists, and office managers to reach solutions that best serve the needs of your patients and staff.
• I-131 Order I-131 Form.pdf
• Veterinary I-131 order Veterinary I-131.pdf
• New Customer Information Information Form.pdf
• Order Form Order Form.pdf
• Full hot lab equipment available.
Why LEU Tc-99m?
The American Medical Isotope Production Act signed by President Obama was signed in 2013. It is part of a multi-nation effort to reduce the use of “weapons grade” HEU. The Act along with the Center for Medicare & Medicaid Services (CMS) announcement for additional reimbursement for non-HEU diagnostic doses is a push for our industry to utilize LEU Tc-99m doses.
Uranium is used in the production of molybdenum (M0-99) which is the parent isotope of technetium (Tc-99), used in millions of diagnostic procedures annually. The United States has no domestic facilities for Mo-99. The Safari reactor in South Africa and the Opal reactor in Australia are the only facilities that can supply LEU Tc-99m-derived raw product.
HEU vs. LEU TechneLite®: Fact vs. Fiction
MYTH: LEU-sourced Mo-99 is not equivalent to HEU-sourced Mo-99.
FACT: LEU and HEU-sourced Mo-99 are equivalent in performance and use as recognized by FDA approval of LEU-produced Mo-99 generators. Lantheus’ TechneLite® generators, using a blend of HEU and LEU, were approved by the FDA for commercial use in 2010 and have been routinely used in the U.S. market since 2011. The only difference between the LEU TechneLite® generator and the standard TechneLite® generator is that LEU TechneLite® is produced using Mo-99 sourced from at least 95 percent LEU instead of HEU. Lantheus receives LEU-sourced Mo-99 from NTP Radioisotopes and the Australian Nuclear Science and Technology Organization (ANSTO).
Low Residual Syringes
For years we have urged our syringe suppliers to come up with a syringe lubricant that would not hold residual radioactivity. Our independent studies have shown some nuclear doses had upwards of 10mCi RESIDUAL left in the syringe. We have finally sourced sterile 3mL and 5mL syringes that cut the residual radioactivity by more than 4 times the BD brand! This allows our end user to get the most out of their nuclear medicine doses insuring accuracy when dosing your patients. We are about bringing efficiency to your department. You can be assured residual activity will no longer be a problem from our pharmacy!
Reimbursement Revenue Solutions
Barbara Ossias of Reimbursement Revenue Solutions LLC is our go-to expert in the medical reimbursement world. Her team of experts will assist you in getting the right code, right amount, and letting you know of any potential changes in the future. Give her a call today but be sure to mention you are a WCNP customer!
Barbara J. Ossias Reimbursement Revenue Solutions, LLC
1 Tara Boulevard Suite 200 Nashua, NH 03062 Office – 603 324 7173 Mobile – 301 639 0446 Fax – 877 256 2430 www.reimbursementrevenuesolutions.com